Mihai, A. | bioRxiv Science

bioRxiv2025

Neoadjuvant anti-4-1BB confers protection against spontaneous metastasis through low-affinity intratumor CD8+ T cells in triple-negative breast cancer

Neoadjuvant immunotherapy seeks to harness the primary tumor as a source of relevant tumor antigens to enhance systemic anti-tumor immunity through improved immunological surveillance. Despite having revolutionized the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC), a significant portion of patients remain unresponsive and succumb to metastatic recurrence post-treatment. Here, we found that optimally scheduled neoadjuvant administration of anti-4-1BB monotherapy was able to counteract metastases and prolong survival following surgical resection. Phenotypic and transcriptional profiling revealed enhanced 4-1BB expression on tumor-infiltrating intermediate (Tint), relative to progenitor (Tprog) and terminally exhausted (Tterm) T cells. Furthermore, Tint was enriched in low-affinity T cells. Treatment with anti-4-1BB drove clonal expansion of Tint, with reduced expression of tissue-retention marker CD103 in Tprog. This was accompanied by increased TCR clonotype sharing between paired tumors and pre-metastatic lungs. Further interrogation of sorted intratumor T cells confirmed enhanced T cell egress into circulation following anti-4-1BB treatment. In addition, gene signature extracted from anti-4-1BB treated Tint was consistently associated with improved clinical outcomes in BRCA patients. Combinatorial neoadjuvant anti-4-1BB and ablation of tumor-derived CXCL16 resulted in enhanced therapeutic effect. These findings illustrate the intratumor changes underpinning the efficacy of neoadjuvant anti-4-1BB, highlighting the reciprocity between local tissue-retention and distant immunologic fortification, suggesting treatment can reverse the siphoning of intratumor T cells to primary tumor, enabling redistribution to distant tissues and subsequent protection against metastases.

immunology↗

bioRxiv2024

E protein control of NKgammadeltaT cell development through both generation and function of the stereotypic Vgamma1Vdelta6.3 TCR

T cell receptor (TCR) signals regulate important developmental transitions through induction of the E protein antagonist, Id3; however, Id3-deficiency produces paradoxical effects on {gamma}{delta} T cell subsets. Here, we show here that Id3-deficiency attenuates the development of V{gamma}3-expressing {gamma}{delta} T cells, while markedly enhancing the development of V{gamma}1V{delta}6.3-expressing NK{gamma}{delta}T cells. Id3-deficiency does so by regulating both the generation of the stereotypic V{gamma}1V{delta}6.3 TCR expressed by NK{gamma}{delta}T cells and its capacity to support development. Indeed, we determined that the Trav15 segment, which encodes the V{delta}6.3 TCR subunit, is directly bound by E proteins that control its expression. Moreover, once expressed, the resulting V{gamma}1V{delta}6.3 TCR in capable of specifying the innate-like NK{gamma}{delta}T cell fate in a cell-autonomous and developmentally-unrestricted manner that is restrained by the Id3/E axis. Together, these data indicate that the paradoxical behavior of NK{gamma}{delta}T cells in the Id3-deficient setting is entirely determined by its stereotypic V{gamma}1V{delta}6.3 TCR complex.

immunology↗